Morell, A.; Čermáková, L.; Novotná, E.; Laštovičková, L.; Haddad, M.; Haddad, A.; Portillo, R.; Wsól, V.
Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3. Cancers 2020, 12, 3731.
https://doi.org/10.3390/cancers12123731
AMA Style
Morell A, Čermáková L, Novotná E, Laštovičková L, Haddad M, Haddad A, Portillo R, Wsól V.
Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3. Cancers. 2020; 12(12):3731.
https://doi.org/10.3390/cancers12123731
Chicago/Turabian Style
Morell, Anselm, Lucie Čermáková, Eva Novotná, Lenka Laštovičková, Melodie Haddad, Andrew Haddad, Ramon Portillo, and Vladimír Wsól.
2020. "Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3" Cancers 12, no. 12: 3731.
https://doi.org/10.3390/cancers12123731
APA Style
Morell, A., Čermáková, L., Novotná, E., Laštovičková, L., Haddad, M., Haddad, A., Portillo, R., & Wsól, V.
(2020). Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3. Cancers, 12(12), 3731.
https://doi.org/10.3390/cancers12123731